SEC Form 4 · accession 0001821530-26-000002
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward J Dulac III
Officer — EVP, Chief Financial Officer
Period of report
Jul 2, 2026
Accepted (ET)
Jul 6, 2026 · 5:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2026 | S | 4,677 | $18.00 | D | 156,286 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025.